News

The CAP trial was a prospective, randomized, double-blind, 26-week study designed to examine the effects of low-dose versus high-dose Lipitor on hsCRP levels in men and women under

The merger creates a late-stage, publicly traded specialty pharmaceutical company engaged in the development and commercialization of proprietary products that address important therapeutic needs in the fields of

Transgenomic, a biotechnology company, and Power3 Medical Products, a bio-medical company, have signed a definitive collaboration and exclusive licensing agreement for the rights to Power3 Medical’s neurodegenerative biomarkers.

Reported revenues increased 1% to a record $2.65 billion in the fourth quarter of 2008, against $2.62 billion in the 2007 quarter. The quarterly revenue growth reflects the

Most recently, Edward served as chief operating officer of Kuros BioSurgery. At Roche, as global head of disease management, Edward created the company’s first integrated Pharma-Diagnostic approach for

AdvanDx, a provider of advanced molecular diagnostic products, has received the FDA 510(k) clearance for E coli/P aeruginosa PNA FISH to identify Escherichia coli or Pseudomonas aeruginosa directly

The financing will be used to mature the company’s product pipeline of antibody therapeutics, particularly within the field of oncology. Kirsten Drejer, CEO of Symphogen, said: “The current

The accurate measurement of human epidermal growth factor type 2 (HER2) gene expression can assist physicians with treatment decisions for patients with cancers in tissues such as breast,

Garnet will use the proceeds to fund Phase II clinical trials of its proprietary human adult bone marrow-derived cells, as well as manufacturing and development. Safeguard Scientifics and